Grants and Contracts
Congratulations to the following individuals for obtaining extramural funding from
federal, state, and/or independent sources between February 1 and April 30, 2026!
NOTE: If any information has been inadvertently omitted, please contact the editor (dflock@lsuhsc.edu) and a correction will be printed in the next issue of The Pulse.
National Institutes of Health – U01
Lang Wu, PhD (Interdisciplinary Oncology)
“Uncovering Causal Protein Markers to Characterize Pancreatic Cancer Etiology and
Improve Risk Prediction”
National Institutes of Health – R35
Eric Lazartigues, PhD (Cardiovascular Center of Excellence)
“Screening and Validation of miRNA Targets for Neurogenic Hypertension”
Biomedical Advanced Research and Development Authority (BARDA)
Jeffrey E. Carter, MD (Surgery)
In collaboration with GE and Oregon Health & Science University
“Ultrasound Data Collection of Subjects with Smoke Inhalation Injury (SII) for the
Development of AI Tools for Rapid Trauma Assessment”
Pharmaceutical, Professional Society and Private Grants
Shyamal Desai, PhD (Pharmacology, Biochemistry & Experimental Therapeutics)
Ataxia Telangiectasia Children's Project
“ISGylation: A Blood-borne Biomarker to Diagnose and Monitor A-T Disease Progression”
Sagar Kansara, MD (Otolaryngology) (Co-PI)
Louisiana Cancer Research Center New Investigator Award
“The Role of Computed Tomography–Derived Skeletal Muscle Characteristics in Predicting
Short and Long Term Postoperative Outcomes After Surgery for Head and Neck Cancer:
A Retrospective Cohort Study”
Anirudh Mukhopadyay, MD (Ophthalmology)
The Brown Foundation
“Relationship between Inflammatory Liver Disease and Age-Related Macular Degeneration”
Keishla Rodriguez-Graciani, PhD (Physiology)
Research Society on Alcohol
“2026 Nadia Chaudhri Rising Scholar Award (NCRSA) for Travel”
John Steck, MD (Neurosurgery)
Cerapedics Inc.
“Neurosurgery Resident Education”
Shou-Ching Tang, MD, PhD (Medicine - Hematology and Oncology)
NextCure, Inc.
“A Phase I First-in-human, Open-label, Multicenter Study to Investigate the Safety,
Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult
Participants with Advanced Solid Tumors”
Shou-Ching Tang, MD, PhD (Medicine - Hematology and Oncology)
Cogent Biosciences, Inc.
“A Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients with Advanced Solid
Tumors with ERBB2 Genetic Alterations or HER2 Overexpression”
Intramural Grants
Health Disparities
Kevin Sullivan, MD (Surgery)
“Determinants of Delayed or Non-Receipt of Definitive Oncologic Resection After Incidentally
Discovered Gallbladder and Appendiceal Cancer in Medicare Beneficiaries”